2024
DOI: 10.1111/imm.13751
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

Xiu Chen,
Liqiu Kou,
Xiaolu Xie
et al.

Abstract: The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this class of drugs has shown good therapeutic prospects. For example, atezolizumab in combination with bevacizumab has been approved as first‐line treatment for advanced HCC due to significant efficacy. However, sensitiv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 122 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?